2022 VB100 Guangzhou Mini Forum on AI+Pharmaceutical Innovation (Postponed)
In recent years, AI technology has demonstrated significant potential through its impressive performance in new drug development, attracting global attention from the pharmaceutical industry. This has sparked a multitude of discussions: Can “AI + new drug development” truly break the bottlenecks plaguing traditional drug R&D? And can it lead the future trends of the industry?
To raise awareness of AI-driven new drug development, empower the accelerated growth of aggregated enterprises, efficiently shape the city’s distinctive industrial image, and disseminate cutting-edge concepts in healthcare.2022Year 11FebruaryDay (Postponed), VCBeat, VB100, and Eggshell Research Institute will jointly with Hejing Kesheng Plaza atGuangzhou International Bio Island · Hejing Kesheng PlazaHost2022 VB100Guangzhou MiniForum. This forum will be held offline for the first timePublish《2022 AI+ New Drug R&D Industry Research Report》, and invitedAlibaba Cloud Computing Co., Ltd.、Founders of multiple companies in the fields of artificial intelligence and new drug R&D, including Shenzhen X-Unknown Biotechnology Co., Ltd., Shenzhen Aigelin Pharmaceutical Co., Ltd., Shenzhen GTJA Investment Group Co., Ltd., Guangzhou Fermion Technology Co., Ltd., Xili Technology (Shenzhen) Co., Ltd., and Guangzhou Zhirui Pharmaceutical Technology Co., Ltd.,Co-founders, Executives, Industry Researchers, and Investment Institution Experts, centering on the value trends of AI in drug R&D, we facilitate cross-sector collaboration among industry, academia, research institutions, and investors, focusing on cutting-edge developments to jointly create new opportunities for win-win cooperation.
Due to the latest epidemic prevention and control policies in Guangzhou and the management requirements for Bio Island, the forum originally scheduled for Wednesday, November 2 has been postponed. The rescheduled date will be announced separately based on the evolving epidemic situation.
13F, Hejing Kesheng Plaza, No. 66, 68, and 70 Luoxuan Avenue, International Bio Island, Huangpu District, Guangzhou City
VCBeat
VCBeat, founded in 2014, is China’s leading research and media platform for the healthcare industry, serving the National Health Commission, the National Healthcare Security Administration, and the United Front Work Department of the CPC Central Committee.A recognized third-party industrial service provider in the field of medical innovation.Boasting China’s largest innovation and venture capital resource database in the healthcare sector, we provide high-quality media communications, industry research, brand events, as well as investment and financing matchmaking and industrial resource alignment services to enterprises, government bodies, industrial parks, and investment institutions.
VB100
VB100 is a business unit under Eggshell Technology, dedicated to serving governments, industrial parks, and large corporations. By organizing diverse activities such as summits, competitions, forums, roadshows, seminars, and launch events, VB100 connects governments with innovative enterprises and large corporations with innovative startups, fostering collaboration in industrial resources and driving industrial upgrading.
Since its inception, it has expanded its presence to over 30 cities across China, including Beijing, Tianjin, Shanghai, Hangzhou, Wuxi, Shaoxing, Nanjing, Ningbo, Suzhou, Shenzhen, Guangzhou, Zhuhai, Wuhan, Zhengzhou, Xi’an, Chengdu, and Chongqing, hosting more than 300 events and conferences.
VCBeat
VCBeat Research Institute has consistently focused on innovation within the healthcare industry amid transformation driven by a dual-engine strategy. Committed to empowering executives, investors, and policymakers with intellectual support through its data technology capabilities and in-depth industry research, the institute aims to optimize decision-making outcomes, accelerate industrial development, and serve as an industry accelerator. With seven years of accumulated industry resources in the healthcare sector, it maintains the world’s largest database of medical innovation enterprises, comprising approximately 70,000 companies, and has established deep connections with over 20,000 enterprises and institutions.。
Kingsquare Plaza
Biopharmaceutical Innovation Industry Base
Guangzhou International Bio Island Business Landmark
Located at the core of Guangzhou International Bio Island, with direct access to two subway lines, KWG Kesheng Plaza is a landmark-grade commercial office building on the island. It integrates seven key advantages: brand strength, transportation convenience, policy support, ecological environment, product quality, supporting facilities, and smart management. Situated in Guangzhou, the core city of the Greater Bay Area, Kesheng Plaza stands on Guangzhou International Bio Island—a future highland for biotechnology industries in Guangzhou and a national-level bio-industry base. The area boasts convenient intercity transportation, clustered industrial effects, comprehensive supporting services, and preferential policies from Huangpu District.
Event Agenda
Time | Agenda | Guest |
14:00-14:10 | Host's Address | |
14:10-14:20 | Remarks by Co-Organizers | |
14:20-14:45 | Offline Launch of the “2022 AI+ New Drug R&D Industry Research Report” | Chen Xuanhe VCBeat, Senior Researcher at VCBeat |
14:45-15:10 | AI-Powered Intelligent Computing—A New Paradigm for Drug Discovery | Shi Zejing Director of Healthcare Industry Architecture, Alibaba Cloud Computing Co., Ltd. |
15:10-15:35 | Driving Microbiome Drug Development with AI Algorithms | Tan Yan Co-founder and CEO, Shenzhen Xbiome Biotechnology Co., Ltd. |
15:35-16:00 | Uphold Source Innovation, Bridging the Entire Pathway from Drug Discovery to Clinical Application | Li Changqing Co-founder and Chief Medical Officer, Shenzhen Aigelin Pharmaceutical Co., Ltd. |
16:00-16:10 | Tea Break | |
16:10-17:10 | Roundtable Discussion: Multi-Stakeholder Support to Accelerate the Clinical Implementation of New Drugs | Yu Jianlin Shenzhen GTJA Investment Group Co., Ltd. Managing Partner Chen Dong Guangzhou Fermion Technology Co., Ltd. Director of Project Management and Intellectual Property, Partner Li Yang Xili Technology (Shenzhen) Co., Ltd. Co-Founder and Executive Chairman Xie Weidong Guangzhou Zhirui Pharmaceutical Technology Co., Ltd. Founder of Zhirui Pharmaceutical |
Scan the QR code or click the link to register for the conference now.
Registration Link:https://vb100.mike-x.com/SEMIV
Event Inquiry: Ms. Shen
Tel: 18388126612
Email: shen.ql@vcbeat.net
In accordance with Guangzhou’s local epidemic prevention and control policies, the following requirements apply (subject to change; please refer to the latest epidemic prevention and control policies for updates):
1. Attendees traveling to Guangzhou from other regions must apply for the “Yue Kang Code” or “Sui Kang Code” in advance. Entry into Guangzhou is permitted only upon presentation of a negative nucleic acid test result within 48 hours and a green health code on the Big Data Itinerary Card at the airport or high-speed railway station. (Note: Travelers arriving from medium- and high-risk areas must undergo an on-arrival nucleic acid test at the airport or high-speed railway station.)
2. To enter the venue, attendees must present their “Yue Kang Code” or “Sui Kang Code,” a negative nucleic acid test result within 48 hours, and a green status on the Big Data Itinerary Code (note: health codes from other cities are not accepted), and pass a temperature check before admission.
3. Wear masks at all times during the conference.